Published

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: The Australian and New Zealand journal of psychiatry
Date: 2026-07-01
Source: PubMed
DOI: 10.1177/00048674261450390
PubMed: 42198984

Authors

Giri Y Furst P Loo CK Clark SR Tibrewal P

Watch author

Derived topics and classifications

psilocybin Depression Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.2026-07-01

Related papers

Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17 Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025-10-31 Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.Psychiatry research · 2025-08-01 Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.JAMA network open · 2025-07-01 Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’Behavioural Pharmacology · 2026-05-06 Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20 Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01 Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026-06-30